MedTrace Logo

A 10-week Study Evaluating the Efficacy and Safety of PD 0332334 in Patients With Generalized Anxiety Disorder (1)

NCT00658008 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 501

Last updated 2012-11-16

No results posted yet for this study

Summary

This is a 10-week trial that evaluates the efficacy and safety of PD 0332334 in subjects, ages from 18 to 65, with generalized anxiety disorder.

Conditions

  • Generalized Anxiety Disorder

Interventions

DRUG

PD 0332334

Capsules, oral, 175 mg BID, 8 weeks with 2 week taper

DRUG

PD 0332334

Capsules, oral, 225 mg BID, 8 weeks with 2 week taper

DRUG

PD 0332334

Capsules, oral, 75 mg BID, 8 weeks with 2 week taper

DRUG

Paroxetine

Capsules, oral, Paroxetine 20 mg QD, 8 weeks with 2 week taper

DRUG

Placebo

Capsules, oral, placebo bid, 8 weeks with 2 week taper

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-04-30
Primary Completion
2009-03-31
Completion
2009-03-31

Countries

  • United States
  • Hungary
  • Italy
  • Russia
  • South Korea

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00658008 on ClinicalTrials.gov